Pure Biologics

Pure Biologics Financing Cash Flow

The Net Financing Cash Flow of Pure Biologics (PUR.WA) as of Nov 12, 2026 is 5.04 M PLN. In the previous year, Net Financing Cash Flow was 3.98 M PLN — a change of 26.60% (higher).

Financing Cash Flow

5.04 MPLN

YoY

26.60%

Last updated:

Net Financing Cash Flow of Pure Biologics is 2025 5.04 M PLN. Net Financing Cash Flow of Pure Biologics was 2024 3.98 M PLN. It decreases by 26.60% higher compared to the previous year.

The Pure Biologics Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
2.58 M PLN
Jan 1, 2019
8.55 M PLN
Jan 1, 2020
-3.05 M PLN
Jan 1, 2021
49.74 M PLN
Jan 1, 2022
-1.88 M PLN
Jan 1, 2023
24.22 M PLN
Jan 1, 2024
3.98 M PLN
Jan 1, 2025
5.04 M PLN
The Pure Biologics Financing Cash Flow history
YEARFinancing Cash FlowYoY
5.04 MPLN+26.60%
3.98 MPLN-83.57%
24.22 MPLN-1,390.94%
-1.88 MPLN-103.77%
49.74 MPLN-1,730.12%
-3.05 MPLN-135.67%
8.55 MPLN+231.51%
2.58 MPLN-10.94%
2.90 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

Net Financing Cash Flow of Pure Biologics is 5.04 M PLN in 2025.

Net Financing Cash Flow of Pure Biologics changed from 3.98 M PLN to 5.04 M PLN, representing a 26.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Pure Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Pure Biologics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pure Biologics